Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980833 · ClinicalTrials.gov registry record · Phase 2
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
A Phase 2 study of PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 6
- Study locations
NCT04980833 is a Phase 2 study of PIK3CA-related Overgrowth Spectrum (PROS) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 41 participants, below the 196-participant average among 3 other PIK3CA-related Overgrowth Spectrum (PROS) trials with a reported enrollment target (79% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT04980833, a Phase 2 study of PIK3CA-related Overgrowth Spectrum (PROS), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term safety and efficacy of alpelisib, in pediatric and adult participants with PROS.
Conditions Studied
Interventions
- DRUG Alpelisib
Study Locations (6)
Other
- Novartis Investigative Site - Dijon
- Novartis Investigative Site - Montpellier
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Dublin
- Novartis Investigative Site - Madrid
Massachusetts
- Boston Childrens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2027-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04980833
The ClinicalTrials.gov registry entry for NCT04980833 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 3 other PIK3CA-related Overgrowth Spectrum (PROS) trials with a reported enrollment target (79% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PIK3CA-related Overgrowth Spectrum (PROS) appearing as the primary indexed condition, and to 1 intervention - of which Alpelisib is the first listed.
NCT04980833 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04980833 about?
NCT04980833 is a clinical study titled "Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)". This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term safety and efficacy of alpelisib, in pediatric and adult participants with PROS.
What is the current status of trial NCT04980833?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-01-27. Estimated completion is 2027-07-22.
What conditions does trial NCT04980833 study?
This clinical trial studies the following conditions: PIK3CA-related Overgrowth Spectrum (PROS).
What interventions are being tested in trial NCT04980833?
The interventions under investigation include: Alpelisib (DRUG).
Who is sponsoring clinical trial NCT04980833?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04980833 being conducted?
This trial has 6 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PIK3CA-related Overgrowth Spectrum (PROS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
RECRUITING · Phase 2
-
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
RECRUITING · Phase 2
-
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.